OncologyPRO is the home of ESMO’s educational and scientific resources

Patients with pancreatic ductal adenocarcinoma and other non-CRC gastrointestinal tumours with a KRASG12C mutation have achieved partial responses and stable disease with adagrasib

From ASCO GI 2022:
Patients with resectable microsatellite instability-high and mismatch repair-deficient gastro-oesophageal junction or gastric adenocarcinoma may benefit from preoperative nivolumab and ipilimumab

Lenvatinib plus pembrolizumab offer significantly longer survival than chemotherapy for advanced endometrial cancer patients who have progressed after platinum-based chemotherapy

Men with localised prostate cancer undergoing definitive radiotherapy are significantly less likely to develop metastatic disease if given androgen deprivation therapy

A non-invasive cell collection system can be used to classify the risk of high-risk dysplasia and cancer in patients with Barrett’s oesophagus and guide the need for endoscopy

Researchers advise against use of pathological complete response as a surrogate for disease-free and overall survival in neoadjuvant therapy trials for early breast cancer

The risk of adverse events with immune checkpoint inhibitor therapy is unaffected by receipt of radiotherapy in the previous 90 days

Apatinib offers significant clinical benefits, with a manageable safety profile, for patients with progressive, locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer